These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 28367663

  • 1. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [Abstract] [Full Text] [Related]

  • 2. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [Abstract] [Full Text] [Related]

  • 3. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 4. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [Abstract] [Full Text] [Related]

  • 6. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
    Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R, NORD-STAR study group.
    BMJ; 2020 Dec 02; 371():m4328. PubMed ID: 33268527
    [Abstract] [Full Text] [Related]

  • 7. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.
    Clin Exp Rheumatol; 2012 Dec 02; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [Abstract] [Full Text] [Related]

  • 8. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J, Wiese MD, Proudman SM, Foster DJ, Upton RN.
    Br J Clin Pharmacol; 2015 May 02; 79(5):777-88. PubMed ID: 25394211
    [Abstract] [Full Text] [Related]

  • 9. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.
    Clin Exp Rheumatol; 2011 May 02; 29(3):500-5. PubMed ID: 21640044
    [Abstract] [Full Text] [Related]

  • 10. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG.
    Ann Rheum Dis; 2015 Jan 02; 74(1):89-95. PubMed ID: 24081439
    [Abstract] [Full Text] [Related]

  • 11. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.
    Arthritis Rheum; 2011 Oct 02; 63(10):2865-72. PubMed ID: 21647867
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 02; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 13. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
    Levitsky A, Wick MC, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, van Vollenhoven RF, Rantalaiho V.
    Clin Exp Rheumatol; 2016 Jan 02; 34(6):1065-1071. PubMed ID: 27607411
    [Abstract] [Full Text] [Related]

  • 14. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J, De Bandt M, Lukas C, Morel J, Combe B.
    J Rheumatol; 2017 Jun 02; 44(6):773-779. PubMed ID: 28412710
    [Abstract] [Full Text] [Related]

  • 15. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
    Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M, NEO-RACo Study Group.
    Ann Rheum Dis; 2014 Nov 02; 73(11):1954-61. PubMed ID: 23908187
    [Abstract] [Full Text] [Related]

  • 16. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.
    Versteeg GA, Steunebrink LMM, Vonkeman HE, Ten Klooster PM, van der Bijl AE, van de Laar MAFJ.
    Clin Rheumatol; 2018 May 02; 37(5):1189-1197. PubMed ID: 29388086
    [Abstract] [Full Text] [Related]

  • 17. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T, Asikainen J, Kokko A, Hannonen P, Sokka T.
    J Rheumatol; 2016 Apr 02; 43(4):699-706. PubMed ID: 26879355
    [Abstract] [Full Text] [Related]

  • 18. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.
    Lancet; 2016 Jul 23; 388(10042):343-355. PubMed ID: 27287832
    [Abstract] [Full Text] [Related]

  • 19. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May 23; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 20. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
    Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J, FIN-RACo Trial Group.
    Clin Exp Rheumatol; 2006 May 23; 24(6):636-42. PubMed ID: 17207378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.